Drug intelligence / Profile preview

LIGHT-PSMA-CART

Development stage: Phase 1
Lead developer: BRL Medicine
Modality: CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies
Administration: Intravenous

Overview

LIGHT-PSMA-CART is an autologous CAR T-cell therapy designed to treat castrate-resistant prostate cancer. It involves lentivirally transduced T cells engineered to express a chimeric antigen receptor (CAR) specific for Prostate-Specific Membrane Antigen (PSMA) found on prostate cancer cells. Additionally, these CAR T cells are co-engineered to express LIGHT (TNFSF14), a tumor necrosis factor superfamily member, which aims to enhance CAR T-cell trafficking and cytotoxicity by reversing the immunosuppressive tumor microenvironment and promoting the formation of tertiary lymphoid structures.

Other names: PSMA-CART cellsAutologous PSMA-specific chimeric antigen cells co-expressing LIGHT

Targets

PSMA (Prostate-specific membrane antigen)

Beyond the preview

Go deeper on LIGHT-PSMA-CART.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on LIGHT-PSMA-CART.

Explore the full profile